Related Experiment Video
Updated: Mar 28, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Update on hepatitis C: Direct-acting antivirals
Leon L Seifert1, Ryan B Perumpail1, Aijaz Ahmed1
1Leon L Seifert, Department of Transplantation Medicine, University Hospital Münster, 48149 Münster, Germany.
Abstract:
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Subviral Agents
Antihypertensive Drugs: Direct Renin Inhibitors

